Shopping Cart
Remove All
Your shopping cart is currently empty
HeFi-1 is a mouse anti-CD30 IgG1 monoclonal antibody that targets the ligand-binding site on CD30. It can inhibit the growth of tumor cells with high CD30 expression and induce eosinophil apoptosis (apoptosis). HeFi-1 is applicable in research on cancer or inflammatory diseases, such as anaplastic large cell lymphoma (ALCL) and asthma.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
| Description | HeFi-1 is a mouse anti-CD30 IgG1 monoclonal antibody that targets the ligand-binding site on CD30. It can inhibit the growth of tumor cells with high CD30 expression and induce eosinophil apoptosis (apoptosis). HeFi-1 is applicable in research on cancer or inflammatory diseases, such as anaplastic large cell lymphoma (ALCL) and asthma. |
| In vitro | HeFi-1 (0.1 ng/μL, 1 hour) can specifically bind to Karpas299 cells, achieving a binding rate of over 90%. At a concentration of 20 μg/mL for 48 hours, HeFi-1 significantly inhibits the proliferation of Karpas299 cells and induces G1 phase arrest. Additionally, HeFi-1 (20 μg/mL, 12-24 hours) significantly induces eosinophil apoptosis. |
| In vivo | Administered intravenously at a dose of HeFi-1 (100 μg) once a week for four weeks, the compound significantly prolongs the survival of SCID/NOD wild-type and FcRγ -/- Karpas299 lymphoma-bearing mice. |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.